ClinicalTrials.gg

Program

apraglutide

Also written as “Apraglutide”, “FE203799 GLP-2 analogue” and “FE 203799”.

Its studies are mostly in Short Bowel Syndrome · Graft vs Host Disease · Renal Insufficiency, Chronic · Hodgkin Disease, led by 2 companies.

Furthest: phase 3, since Oct 22, 202012 company-led studies, 2 open or runningNext primary completion: Oct 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ironwood Pharmaceuticals92 open or runningphase 3since Oct 22, 2020Oct 22, 2020Oct 30, 2027phase 3 · NCT05018286
GlyPharma Therapeutics30 open or runningphase 2since Nov 13, 2017Nov 13, 2017none ahead

Also a collaborator on its studies: psi-cro.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 13, 2017First studies: 3 phase 2 studiesNew to GlyPharma TherapeuticsGlyPharma Therapeutics · NCT03417765, NCT03415594, NCT03408132
  2. Oct 22, 2020Ironwood Pharmaceuticals's first study: phase 3 study in Short Bowel SyndromeNew to Ironwood PharmaceuticalsIronwood Pharmaceuticals · NCT04627025 · 164 enrolled · United States, Argentina, Belgium and more
  3. Dec 30, 2020Phase 1 study in Renal Insufficiency, ChronicIronwood Pharmaceuticals · NCT04699032 · 16 enrolled · United States
  4. May 27, 2021Phase 2 study in Short Bowel SyndromeIronwood Pharmaceuticals · NCT04964986 · 10 enrolled · Belgium, France
  5. Jul 6, 2021Phase 3 study in Short Bowel SyndromeIronwood Pharmaceuticals · NCT05018286 · 158 enrolled · United States, Argentina, Belgium and more
  6. Feb 8, 2022Phase 2 study in Graft vs Host DiseaseIronwood Pharmaceuticals · NCT05415410 · 31 enrolled · United States, Germany, Portugal and more
  7. Jan 20, 2023Phase 1 study in Hepatic ImpairmentIronwood Pharmaceuticals · NCT05706623 · 16 enrolled · Germany, Slovakia
  8. Feb 22, 2023Phase 1 study in Healthy SubjectsIronwood Pharmaceuticals · NCT05995704 · 42 enrolled · Netherlands
  9. Jul 11, 2023Phase 1 study in Healthy SubjectsIronwood Pharmaceuticals · NCT06002555 · 34 enrolled · Netherlands
  10. Jul 12, 2026Phase 3 study in Short Bowel SyndromeIronwood Pharmaceuticals · NCT07742735 · 124 planned · United States, Argentina, Australia and more

Ahead

  1. Oct 30, 2027Primary completion: phase 3 study in Short Bowel SyndromeIronwood Pharmaceuticals · NCT05018286
  2. Oct 2028Primary completion: phase 3 study in Short Bowel SyndromeIronwood Pharmaceuticals · NCT07742735

TargetBeta

GCG →read by rule
“A synthetic, long-acting glucagon-like peptide-2 (GLP-2) agonist, with intestinotrophic activity”NCIt, by rule

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07742735Short Bowel Syndrome · United States, Argentina, Australia and more3RecruitingIronwood PharmaceuticalsOct 2028124
NCT06002555Healthy Subjects · Netherlands1CompletedIronwood PharmaceuticalsSep 22, 202334
NCT05995704Healthy Subjects · Netherlands1CompletedIronwood PharmaceuticalsJul 24, 202342
NCT05706623Hepatic Impairment · Germany, Slovakia1CompletedIronwood PharmaceuticalsApr 4, 202316
NCT05415410Graft vs Host Disease · United States, Germany, Portugal and more2TerminatedIronwood PharmaceuticalsDec 17, 202431
NCT05018286Short Bowel Syndrome · United States, Argentina, Belgium and more3Active, not recruitingIronwood PharmaceuticalsOct 30, 2027158
NCT04964986Short Bowel Syndrome · Belgium, France2CompletedIronwood PharmaceuticalsJun 6, 202310
NCT04699032Renal Insufficiency, Chronic · United States1CompletedIronwood PharmaceuticalsJul 5, 202116
NCT04627025Short Bowel Syndrome · United States, Argentina, Belgium and more3CompletedIronwood PharmaceuticalsJan 2, 2024164
NCT03408132Short Bowel Syndrome · Denmark2CompletedGlyPharma TherapeuticsOct 28, 20198
NCT03415594Short Bowel Syndrome · Denmark2CompletedGlyPharma TherapeuticsNov 21, 20198
NCT03417765Lymphoma2WithdrawnGlyPharma TherapeuticsMar 31, 20190

How it is read

Names in the registry

  • “Apraglutide”, 8 entries
  • “FE203799 GLP-2 analogue”, 2 entries
  • “apraglutide”, 1 entry
  • “FE 203799”, 1 entry
  • “FE203799”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
apraglutide (Ironwood Pharmaceuticals): development program | ClinicalTrials.gg